Purpose: The purpose of this guideline amendment, herein referred to as the amendment, is
to incorporate relevant newly published literature to better provide a clinical framework for …

Importance Women with refractory urgency urinary incontinence are treated with sacral
neuromodulation and onabotulinumtoxinA with limited comparative information. Objective …

Botulinum neurotoxins (BoNTs) cause flaccid paralysis by interfering with vesicle fusion and
neurotransmitter release in the neuronal cells. BoNTs are the most widely used therapeutic …

Obesity prevalence is increasing worldwide, with significant healthcare implications. We
searched PubMed/MEDLINE, Embase and the Cochrane Library for articles registered until …

Objective To assess construct validity of the Patient Global Impression scales (Severity [PGI‐
S], Bother [PGI‐B] and Improvement [PGI‐I]) for symptoms of detrusor overactivity (DO) …

The American Urological Association guidelines for the management of non-neurogenic
overactive bladder (OAB) recommend the use of OnabotulinumtoxinA, sacral …

The purpose of the study was to determine the efficacy and safety of nonantimuscarinic
treatments for overactive bladder. Medline, Cochrane, and other databases (inception to …

The standard treatment for overactive bladder starts with patient education and behavior
therapies, followed by antimuscarinic agents. For patients with urgency urinary incontinence …

OnabotulinumtoxinA (BT-A) is used in different medical fields for its beneficial effects. BT-A,
a toxin originally produced by the bacterium Clostridium botulinum, is widely known for its …

AIMS To review and assess the definitions of drug resistance and the evidence supporting
treatment for drug resistant overactive bladder/detrusor overactivity (OAB/DO). METHODS …